This article first appeared on GuruFocus .
-
Cash and Cash Equivalents:$5.65 million as of the end of June 2026, up from $3 million at year-end.
-
Net Proceeds from Financing:$5.86 million generated from two financing events in June 2026.
-
Total Operating Expenses (Six Months):$5.34 million, an increase of $1 million compared to the prior year.
-
Operating Expenses (Q2):$2.95 million, an increase of $405,000 compared to the same period in 2025.
-
Net Loss (Six Months):$5.25 million through the end of June 2026.
-
Net Loss (Q2):$2.88 million for the quarter.
-
Cash Used in Operations:$3.6 million across the first half-year.
-
Non-Dilutive Capital:Approximately $20 million to date from federal grants.
Release Date: August 20, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
NCT pilot-scale production with Cayman Chemical achieved 99.6% purity and 99% feedstock conversion, demonstrating the process works outside the lab at scale.
-
Process optimization boosted NCT productivity by 10x, with 67% more product per liter and 5x faster reaction times, improving economic attractiveness.
-
The company secured approximately $20 million in non-dilutive funding from NIH, DOE, and NSF, including a $2 million SBIR grant for cannabinoid development.
-
Manufacturing partner selection is on track for Q3 2026, with multiple qualified options providing supply chain flexibility and risk management.
-
The New Ideas Engine has five molecules in proof-of-concept evaluation, showcasing the platform's potential beyond NCT and cannabinoids.
-
The company's asset-light model leverages external manufacturing, avoiding heavy capital expenditure on facilities.
-
NCT targets the HNF4 alpha mechanism, which is underserved in the market, offering potential in both nutraceutical and pharmaceutical applications.
Negative Points
-
Cash position is only $5.65 million, sufficient to fund operations only into the end of 2026, raising near-term liquidity concerns.
-
The company is pre-revenue, with net losses of $5.25 million in the first half of 2026, and operating expenses are increasing.
-
The June 2026 financings were dilutive, issuing over 732,000 shares and warrants, increasing share count to 9.3 million.
-
The company has not yet secured a commercial launch partner for NCT, with details expected only by Q4 2026.
-
The strategy shift from early-stage partnerships to later-stage development has caused delays and shareholder pain, as acknowledged by the CEO.
-
The company faces challenges in attracting first partners due to the novelty of its platform, leading to difficult negotiations and potential value concessions.
-
The timeline for NCT market launch is targeted for mid-2027, but this is subject to risks including technology transfer and regulatory approvals.
Q & A Highlights
Q: Does the platform potentially give pharma, or even other industries, access to new chemical space that they couldn't get to before? A: Michael Heltzen (CEO) confirmed this is the core competitive advantage on the pharma side, describing it as a new generation of medicinal chemistry. He explained that the platform uses enzymes to elegantly control how molecules are taken apart or put together, a capability they refer to as "BioClick." This allows them to create molecules that would be too expensive or impure to make using traditional chemistry, which is a key "aha" moment for medicinal chemists.
Q: Does the 10x productivity improvement announced yesterday improve upon the projected high gross margins, or was it already built into the model? A: Damien Perriman (CCO) stated that the commercialization targets have been improved upon and exceeded. He explained that the company uses a "techno-economic model" that tracks all inputs, including raw material costs and contract manufacturing fees. The 10x productivity gain was a meaningful step change in expectations for NCT's profitability, giving the team high confidence in the product's commercial success.
Q: What are the plans to increase investor awareness and reach to get the story out about the company's milestones? A: Michael Heltzen (CEO) acknowledged that the company's story is now "ready for prime time" after a period of defining its strategy and building its platform. He stated they have engaged with new people and outlets to reach larger audiences. The plan includes attracting more retail investors, who are known for more active trading, and directing interest from family offices to buy in the open market to increase daily trading volume.
Q: For future joint venture partnerships, does eXoZymes expect to receive upfront and milestone payments, or is a partnership mainly based on shared equity in a subsidiary? A: Michael Heltzen (CEO) and Damien Perriman (CCO) explained that the deal structure will depend on the specific business case and partner. They view it as a portfolio approach, where early deals like NCT may involve owning more equity to maximize value, while future deals might be more transactional, focusing on royalty streams. The priority is speed to market and mobilizing capabilities effectively, rather than getting an extra percent on an equity deal.
Q: What are the strategic benefits of building cell-free solutions for santalene, even though its market opportunity is smaller than other programs? A: The team explained that the santalene project, funded by an NSF grant, provides a "ride-along" opportunity to develop a new toolset for driving cell-free reactions more efficiently. This new tool could lower costs for any target product in the future. Additionally, it allows the company to explore a new class of molecules (fragrance compounds) and be patient in finding its market value, while the primary benefit is the advancement of their core production capabilities.
Q: Given that eXoZymes' expertise is in building cell-free enzymatic pathways, what expertise does the company have in medicinal chemistry and rational design? A: Tyler Korman (CSO) stated that their core expertise lies in enzyme engineering and understanding enzyme specificity and promiscuity. This allows them to add different inputs, like amino acid analogs, to create new molecules with novel composition of matter for IP. They leverage a network of consultants and partners to match these capabilities to specific indications of interest.
Q: What are the things that a nutraceutical or pharma company wants to see before signing a deal for a product, and how are these activities tracking? A: Damien Perriman (CCO) noted that pharma companies typically want to see animal results against targeted indications. However, he highlighted that the metabolic health space, particularly obesity, is rich in dealmaking, making companies more active. He also emphasized a growing interest in mechanisms, not just molecules, and pointed to HNF4 alpha, the mechanism targeted by NCT, as an underserved and open-space opportunity for partnering.
Q: Can you unpack the statement that the HNF4 alpha drug receptor has two distinct roles in different organs? A: Tyler Korman (CSO) explained that HNF4 alpha is predominantly found in the liver, where it manages metabolism, but it is also found in the gut with a nearly identical isoform (about 90% the same). This means the same ligand, like NCT, can affect two different locations in the body, impacting gut health and overall metabolism, including fatty acid oxidation. This represents two very large markets and "two shots on goal" on the pharma side alone.
Q: What is the company's cash position and how is it managing its finances? A: Fouad Nawaz (VP of Finance) reported that cash and cash equivalents stood at $5.65 million as of the end of June 2026. The company completed two financing events in June, generating net proceeds of $5.86 million. Operating expenses for the first half of 2026 were $5.34 million, with a net loss of $5.25 million. The company is disciplined in its spending and continues to explore non-dilutive funding opportunities, strategic partnerships, and government grants.
Q: Why did the company shift its strategy from signing many development deals to focusing on building its own product assets like NCT? A: Michael Heltzen (CEO) explained that the old strategy of licensing the platform was hindered by a "first-mover" problem, where no established company wanted to be the first to take on the risk of a new technology. This led to steep discounts and unfavorable terms. The new strategy involves de-risking projects internally, proving the technology works at scale, and then entering partnerships from a position of strength, allowing the company to retain more upside and value.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
